Skip to main content
Premium Trial:

Request an Annual Quote

Aussie Life Science Distributor to Oversee CombiMatrix s Japanese Subsidiary

NEW YORK, Jan. 26 (GenomeWeb News) - CombiMatrix has transferred to partner INBIO the day-to-day operational responsibility and majority ownership of its Japanese subsidiary, CombiMatrix KK, and has expanded its distribution agreement with INBIO to include Japan, CombiMatrix parent Acacia Research said today.

As part of the deal, INBIO, which is based in Australia, has obtained 67 percent of the voting interests in the KK subsidiary, which is based in Tokyo. "INBIO will assume all operational and financial responsibilities of the KK including its liabilities," Acacia said.

 

The CombiMatrix group will manage new business and strategic relationships and opportunities from its USheadquarters in Mukilteo, Wash.The KK unit and INBIO will "focus exclusively on sales of the CombiMatrix group's products and services," Acacia added.

"The experience of INBIO executives in the Japanese markets as well as their proximity will enable more efficient management of our now jointly owned Japanese subsidiary," Amit Kumar, president and CEO of CombiMatrix, said in a statement.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.